MGTX News and Press, MeiraGTx Holdings plc From 05/03/23

2023-05-03 09:13:39 ET Gene therapy company MeiraGTx Holdings ( NASDAQ: MGTX ) has agreed to sell ~10.7M shares at $5.75 per share for aggregate gross proceeds of ~$60M. The company intends to use the proceeds to continue to advance its pipeline of gene therapy assets, as well...

LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 million ordinary shares at a price of $5.75 per share. MeiraGTx anticipates aggre...

LONDON and NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced two abstract presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annu...

2023-03-14 08:41:16 ET MeiraGTx press release ( NASDAQ: MGTX ): FY GAAP EPS of -$2.87. Revenue of $15.9M (-57.8% Y/Y). For further details see: MeiraGTx GAAP EPS of -$2.87, revenue of $15.9M

-   Announced positive clinical data from AQUAx AAV-hAQP1 Phase 1 trial for treatment of Grade 2/3 Radiation-Induced Xerostomia in December 2022 -   Announced positive top-line data from the MGT009 Phase 1/2 clinical study demonstrating safety and improvement in ...

Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohorts Increases in whole saliva flow rates were seen in both unilateral and bilateral cohorts Overall degree ...

LONDON and NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present clinical data from the Company’s AAV-hAQP1 Ph...

MeiraGTx press release ( NASDAQ: MGTX ): Q3 GAAP EPS of -$0.83. Revenue of $4.82M (-30.5% Y/Y). Shares +1.5% PM. For further details see: MeiraGTx GAAP EPS of -$0.83, revenue of $4.82M

-- Updated Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Now Dosing Patients in Phase 1 Trial Evaluating AAV-GAD Gene Therapy for Parkinson’s Disease -- Rece...

LONDON and NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit 15 poster presentations at the European Society of Gene and Cell Therapy (ESGCT)...